|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0085 - 0.0090|
|52 Week Range||0.0085 - 0.0500|
|Beta (3Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.56|
ATLANTA, March 27, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the year ended December.
GeoVax (GOVX) recently had its Ebola Vaccine Study published in the Atlas of Science. The article, entitled Single Dose Protection Against Ebola Virus Challenge, highlights the importance of an Ebola vaccine that can be stored at room temperature and minimizes severe adverse events. GeoVax’s GEO-EM01 has demonstrated these characteristics in preclinical studies.
GeoVax Ebola Vaccine Provides Potential for 100% Protection from Single-Dose ATLANTA, GA, March 19, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech Award ATLANTA, GA, March 12, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today provided an update on its progress and development programs. David Dodd, GeoVax President and CEO, commented, “We continue to advance GeoVax’s development programs on multiple fronts with an expanding list of world-class government, academic and corporate collaborators, as further described in this update. Going forward, we will continue to evaluate options to secure the capital needed to proceed with our business plan, especially to advance further programs into human clinical testing.
Supported by Contract from U.S. Agency for International Development (USAID) ATLANTA, GA, March 04, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
Comments on HHS Initiative “Ending the HIV Epidemic: A Plan for America” ATLANTA, GA, Feb. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology.
Today, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day. GeoVax is commemorating the day by celebrating the progress toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African-Americans.
During Tuesday night’s State of the Union address, President Donald Trump asked Congress to support his goal of eliminating the HIV epidemic in America within 10 years. GeoVax’s President and CEO, David Dodd, responded today. “We applaud President Trump for using such a high-profile setting to bring attention to the continued HIV epidemic in the United States,” Mr. Dodd commented.
GeoVax Zika Vaccine Provides Potential for 100% Protection & Reduced Side-Effect Risks ATLANTA, GA, Jan. 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
ATLANTA, GA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, announced that Senior Scientist, Mary Hauser, PhD, will deliver a presentation, entitled “Development of a Safe and Effective Single-Dose Vaccine for Emerging Infectious Diseases, Preclinical Data for Zika, Ebola and Lassa Fever as Examples,” during the 2019 American Society for Microbiology (ASM) Biothreats Conference, being held January 29-31, 2019 in Arlington, Virginia. Dr. Hauser will discuss GeoVax’s “Plug and Play” vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated. The MVA-VLP platform has several advantages including the ability to use single inoculations to achieve full protection.
We visited with GeoVax (GOVX) management at their facilities in Smyrna, Georgia to review their key programs and identify the expected path forward for the company. Over the last few years, GeoVax has expanded from a single program developing an HIV vaccine to a platform company that is using its modified vaccinia Ankara virus-like particles (MVA-VLP) technology to address a broad portfolio of hemorrhagic fevers, hepatitis viruses, malaria and cancer. GeoVax’s most advanced program is a vaccine for human immunodeficiency virus (HIV), Clade B, which has completed a Phase IIa trial.
Potential for Addressing Multiple Infectious Disease Targets ATLANTA, GA and OXFORD, UK, Jan. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
David Dodd, GeoVax President and CEO, stated, “The ongoing Ebola outbreak in DRC is now among the deadliest in history, second only to the 2014-16 outbreak in several African nations that infected 28,652 people and killed 11,325. As of December 8, 2018, there have been 446 confirmed cases of Ebola in the Congo with 235 deaths, which disproportionally affected women and young children. There is currently no licensed vaccine to protect people from the Ebola virus. An experimental vaccine with a limited supply is being used in a “ring vaccination” approach.
World AIDS Day is a global initiative to raise awareness, fight prejudice, and improve education about HIV and AIDS. “The U.S. federal theme for the 2018 World AIDS Day observance is Saving Lives through Leadership and Partnerships,” commented David Dodd, President & CEO of GeoVax. “GeoVax is committed to an AIDS-free generation through vaccine development, and today we would like to recognize and thank our many collaborators and partners, both current and past, who have helped advance our vaccine candidates.
ATLANTA, GA, Nov. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today provided an update of the clinical development plan for its preventive vaccine (GOVX-B11) for clade B HIV. The HIV Vaccine Trials Network (HVTN) is moving forward with plans for a phase 1 trial, designated HVTN 132, which will be a multi-center, randomized, double-blind trial, enrolling up to 70 healthy adults. The primary objectives of the trial will be to assess the safety, tolerability and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11, in combination with protein boosts.
By John Vandermosten, CFA OTC:GOVX READ THE FULL GOVX RESEARCH REPORT GeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update ...
The project will include the design, construction, and characterization of multiple immunotherapeutic vaccine candidates using GeoVax’s MVA-VLP vaccine platform combined with certain novel peptide PD-1 checkpoint inhibitors developed by Leidos. The vaccine design, construction, and characterization will be performed at GeoVax with further analysis conducted by Leidos. GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated.
GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology ATLANTA, GA, Nov. 13, 2018 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc..
ATLANTA, Nov. 08, 2018 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its.
Plug & Play Platform Continues to be Recognized for Distinct Benefits ATLANTA, GA, Nov. 07, 2018 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology.
The new article, published by researchers from The University of Texas Medical Branch at Galveston and the Faculty of Medicine of Sao Jose do Rio in Brazil, describes the detection of Zika virus in dead monkeys found in several areas in Brazil. Zika virus is spread among humans predominately via mosquitos.
By John Vandermosten, CFA OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) participated in several conferences in the last weeks of October, including the HIVR4P conference in Madrid, Spain, the ISV in Atlanta, Georgia ...